The median time between samples was 42 months, and the patients were primarily treated with fludarabine-based regimens.5 Of the 22 validated CLL-specific DMRs, 16 associated genes were differentially expressed between timepoints (PFDR < 0.05), while a further gene, RNF144A, approached significance (PFDR < 0.10). Here, RNF144A is linked to B-cell chronic lymphocytic leukemia.